Management of papillary microcarcinoma: Primum non nocere?

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 4, 2012, Pages 1169-1172

  Wartofsky, Leonard ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; RADIOACTIVE IODINE; THYROTROPIN;

ASPIRATION BIOPSY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; EDITORIAL; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; THYROID PAPILLARY CARCINOMA; THYROID PAPILLARY MICROCARCINOMA; THYROIDECTOMY; TUMOR VOLUME;

BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; HUMANS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; THYROID NEOPLASMS; TUMOR BURDEN; UNITED STATES;

EID: 84859534224     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1465     Document Type: Editorial

References (32)

1. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association Management Guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
2. Nilsson IL, Arnberg F, Zedenius J, Sundin A 2011 Thyroid incidentaloma detected by fluorodeoxyglucose positron emission tomography/ computed tomography: practical management algorithm. World J Surg 35:2691-2697
3. 18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor. J Clin Endocrinol Metab 95:3182-3188
4. Kang KW, Kim SK, Kang HS, Lee ES, Sim JS, Lee IG, Jeong SY, Kim SW 2003 Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88:4100-4104 (Pubitemid 37153705)
5. Burguera B, Gharib H 2000 Thyroid incidentalomas. Prevalence, diagnosis, significance, and management. Endocrinol Metab Clin North Am 29:187-203
6. Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, Tomoda C, Takamura Y, Kobayashi K, Miya A 2010 An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 34:28-35
7. Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, Thompson GB, Sebo TJ, Goellner JR 2008 Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 144:980-987; discussion 987-988
8. Lee KJ, Cho YJ, Kim SJ, Lee SC, Kim JG, Ahn CJ, Lee DH 2011 Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size. World J Surg 35:318-323
9. Kim TY, Hong SJ, Kim JM, Gu Kim W, Gong G, Ryu JS, Kim WB, Yun SC, Shong YK 2008 Prognostic parameters for recurrence of papillary thyroid microcarcinoma. BMC Cancer 8:296
10. Zhang L, Wei W-J, Ji Q-H, Zhu Y-X, Wang Z-Y, Huang C-P, Shen JQ, Li D-S,WuY 2012 Risk factors for neck lymph node metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab 97:1250-1257
11. Lee SL 2010 Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw 8:1277-1286; quiz 1287
12. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I 2011 Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 117:4439-4446
13. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD 2008 The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504-515 (Pubitemid 351240823)
14. Bernet V 2010 Approach to the patient with incidental papillary microcarcinoma. J Clin Endocrinol Metab 95:3586-3592
15. Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma S, Kuma K, MiyauchiA2003 An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13:381-387 (Pubitemid 36588523)
16. Haymart MR, Cayo M, Chen H 2009 Papillary thyroid microcarcinomas: big decision for a small tumor. Ann Surg Oncol 16:3132-3139
17. Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM 2011 The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid 21:231-236
18. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL,MaxonHR, Sherman SI 2009 Recurrence after treatment of micropapillary thyroid cancer. Thyroid 19:1043-1048
19. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A 2004 Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab 89:3713-3720 (Pubitemid 39071462)
20. Pearce EN, Braverman LE 2004 Editorial: papillary thyroid microcarcinoma outcomes and implications for treatment. J Clin Endocrinol Metab 89:3710-3712 (Pubitemid 39071461)
21. Mercante G, Frasoldati A, Pedroni C, Formisano D, Renna L, Piana S, Gardini G, Valcavi R, Barbieri V 2009 Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study of 445 patients. Thyroid 19:707-716
22. Durante C, Attard M, Torlontano M, Ronga G, Monzani F, Costante G, Ferdeghini M, Tumino S, Meringolo D, Bruno R, De Toma G, Crocetti U, Montesano T, Dardano A, Lamartina L, Maniglia A, Giacomelli L, Filetti S 2010 Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. J Clin Endocrinol Metab 95:4882-4888
23. Tuttle RM, Rondeau G, Lee NY 2011 A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer. Cancer Control 18: 89-95
24. Malandrino P, Latina A, Marescalco S, Spadaro A, Regalbuto C, Fulco RA, Scollo C, Vigneri R, Pellegriti G 2011 Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab 96:1703-1709
25. Lombardi CP, Bellantone R, De Crea C, Paladino NC, Fadda G, Salvatori M, Raffaelli M 2010 Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area. World J Surg 34:1214-1221
26. Yu XM, Wan Y, Sippel RS, Chen H 2011 Should all papillary thyroid microcarcinomas be aggressively treated. Ann Surg 254:653-660
27. Sugitani I, Toda K, Yamada K, Yamamoto N, Ikenaga M, Fujimoto Y 2010 Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 34:1222-1231
28. Silver RJ, Parangi S 2004 Management of thyroid incidentalomas. Surg Clin N Amer 84:907-919 (Pubitemid 38622424)
29. Ito Y, Amino N, MiyauchiA2010 Thyroid ultrasonography. World J Surg 34:1171-1180
30. Park YJ, Kim YA, Lee YJ, Kim SH, Park SY, Kim KW, Chung JK, Youn YK, Kim KH, Park do J, Cho BY 2010 Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF (V600E) mutation, clinicopathological features, and immunohistochemical findings. Head Neck 32:38-45
31. Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM 2010 The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol 17:3294-3300
32. Niemeier LA, Kuffner AH, Song C, Carty SE, Hodak SP, Yip L, Ferris RL, Tseng GC, Seethala RR, Lebeau SO, Stang MT, Coyne C, Johnson JT, Stewart AF, Nikiforov YE 31 August 2011Acombined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer doi: 10.1002/cncr.26425